DentalReach Clinical Contributor:
With studies indicating that 30% of the adult population experience dental sensitivity, ELSENZ powered by BioMin is the product stepping up to the plate. The concept should be tested against diagnosis, prognosis, treatment alternatives, biological cost, patient preference and a measurable review outcome.